Oncodrex is developing a pipeline of drug candidates targeting unique molecular signatures that are drivers of metastases. Oncodrex is developing a companion diagnostic assay that detects unique molecular signature. The scientific program based on preclinical studies aims at selecting patients most likely to respond to Oncodrex’s targeted therapies.
|Indication||Preclinical||Phase1/1b||Phase 2||Anticipated Milestone 2019|
|Companion Diagnostic||Pancreatic Cancer||Results from Confirmatory Study from CLIA Labs|
|Small Molecule Inhbitor||Pancreatic Cancer||Preclinical Efficacy Study|
Oncodrex is an oncology company focused on developing simple biomarker(s) based tests for cancers and precision therapeutics. Oncodrex is developing precision therapeutics against unique molecular signatures that drive tumor progression and metastases.